Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Thai CL Policy Estimated Worth $253 Million Over Five Years

This article was originally published in PharmAsia News

Executive Summary

Thailand's policy decision regarding compulsory licensing for key foreign drugs could be worth $253.2 million to the nation over the next five years, the government has estimated. A committee considering whether to keep or drop the compulsory licensing policy is expected to submit the estimate to the Public Health Ministry. The figure is based in part on estimates of the number of new cancer cases expected to be reported this year through 2012. (Click here for more

Table

View full table

Tags:
Latest Headlines

Diversification Gains Momentum As Companies Look To Derisk China

Finance Watch: Earnings Season Brings Job Cuts, Even At Big Pharma

JLABS Korea, The Next Evolution Of J&J’s Innovation Model

Newron’s Add-On Treatment Shows Promise In Newly Popular Schizophrenia Field

See All
UsernamePublicRestriction

Register

SC068124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By